Overview

A Phase II Study of CC-5013 in Myelofibrosis

Status:
Completed

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Celgene Corporation

Treatments:

Lenalidomide
Thalidomide